ストックスクリーナーアプリを入手
2.76
1.43%
-0.04
アフターアワーズ：
2.74
-0.02
-0.72%
前日終値:
$2.80
開ける：
$2.82
24時間の取引高:
897.96K
Relative Volume:
0.76
時価総額：
$133.15M
収益：
-
当期純損益:
$-30.04M
株価収益率:
-1.7468
EPS:
-1.58
ネットキャッシュフロー:
$-27.38M
1週間 パフォーマンス:
+33.98%
1か月 パフォーマンス:
+112.31%
6か月 パフォーマンス:
+91.67%
1年 パフォーマンス:
+21.59%
1日の値動き範囲:
$2.6603
$2.85
1週間の範囲:
$1.975
$2.90
52週間の値動き範囲:
$0.8301
$2.90
Regulus Therapeutics Inc Stock (RGLS) Company Profile
名前
Regulus Therapeutics Inc
セクター
電話
858-202-6300
住所
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
2.76 | 133.15M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | 開始されました | Oppenheimer | Outperform |
| 2024-03-18 | 開始されました | Leerink Partners | Outperform |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 開始されました | Leerink Partners | Outperform |
| 2017-06-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-06 | 繰り返されました | Wedbush | Outperform |
| 2017-01-30 | ダウングレード | Needham | Buy → Hold |
| 2017-01-30 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-11-02 | 繰り返されました | Needham | Buy |
| 2016-07-25 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | FBR Capital | Outperform |
| 2016-06-28 | 繰り返されました | Needham | Buy |
| 2016-06-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-04-13 | 開始されました | Chardan Capital Markets | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-06-09 | 開始されました | Guggenheim | Buy |
| 2015-04-21 | 再開されました | FBR Capital | Outperform |
| 2014-11-24 | 開始されました | Deutsche Bank | Buy |
| 2014-08-07 | 繰り返されました | FBR Capital | Outperform |
| 2013-08-14 | 繰り返されました | Needham | Buy |
すべてを表示
Regulus Therapeutics Inc (RGLS) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
Does Regulus Therapeutics Inc (NASDAQ:RGLS) Look Expensive At $2.80? Here’s How To Know. - Marketing Sentinel
Should You Buy Regulus (RGLS) After Golden Cross? - Yahoo
Regulus Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Regulus Therapeutics Inc (RGLS) Stock: Navigating a Year of Volatility - investchronicle.com
Plus Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.0899: Will the Stock Break Through? - investchronicle.com
Analytical Overview: Regulus Therapeutics Inc (RGLS)’s Ratios Tell a Financial Story - DWinneX
Taking the lead: Regulus Therapeutics Inc (RGLS) - Sete News
A closer look at Regulus Therapeutics Inc (RGLS)’s stock price trends - uspostnews.com
10 Best Rising Penny Stocks to Buy According to Analysts - Insider Monkey
Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average – Time to Sell? - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - Longview News-Journal
microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st
Regulus Therapeutics (NASDAQ:RGLS) Raised to “Overweight” at Wells Fargo & Company - Defense World
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
H.C. Wainwright maintains Buy on Regulus stock, $10 target - Investing.com
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus: Q4 Earnings Snapshot - San Antonio Express-News
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Can Regulus Therapeutics' Conference Appearance Signal New MicroRNA Developments? - Stock Titan
Regulus Therapeutics Inc (RGLS) 財務データ
収益
当期純利益
現金流量
EPS
Regulus Therapeutics Inc (RGLS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BALTIMORE DAVID | Director |
Jan 30 '25 |
Buy |
1.06 |
19,610 |
20,787 |
22,169 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 13 '25 |
Sale |
1.26 |
38,547 |
48,693 |
54,634 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
49,546 |
| Hagan Joseph P | Chief Executive Officer |
Jan 13 '25 |
Sale |
1.26 |
115,290 |
145,634 |
222,572 |
| Hagan Joseph P | Chief Executive Officer |
Jan 14 '25 |
Sale |
1.26 |
11,764 |
14,860 |
210,808 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 13 '25 |
Sale |
1.26 |
38,716 |
48,906 |
50,566 |
| CALSADA CRISPINA | Chief Financial Officer |
Jan 14 '25 |
Sale |
1.26 |
5,088 |
6,427 |
45,478 |
| Klassen Preston | President & Head of R & D |
Jan 13 '25 |
Sale |
1.26 |
31,445 |
39,721 |
36,055 |
| Collier Kathryn J | Director |
Jul 25 '24 |
Buy |
1.82 |
4,000 |
7,280 |
6,740 |
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):